Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face

Abstract

Paclitaxel as a single agent has substantial activity against angiosarcoma of the scalp or face, even in patients previously treated with chemotherapy or radiation therapy. Further investigation is warranted to define the optimal treatment dose and schedule.